Navigation Links
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Date:8/3/2009

BOTHELL, WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon to discuss quarterly results.

The webcast can be accessed on the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7912 (U.S. Canada) or 719-325-4897 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
2. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
3. OncoGenex Pharmaceuticals Added to Russell Indexes
4. OncoGenex Pharmaceuticals Files Shelf Registration Statement
5. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
8. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
9. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
10. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
11. OncoGenex Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... The global biotechnology services outsourcing market ... 2025, according to a new report by Grand ... of the function of outsourcing certain clinical and ... services outsourced, clinical trial management and contract manufacturing ... was the first pharmaceutical company to outsource its ...
(Date:1/18/2017)... to a new market research report "In situ Hybridization Market by Technique (FISH, ... Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by MarketsandMarkets, ... 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports Medicine ... Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long Island ... anterior cervical discectomy and fusion on a 42 year old female who was ...
(Date:1/18/2017)... PRUSSIA, PA (PRWEB) , ... January 18, 2017 ... ... clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt ... in engaging panel discussions to examine vital clinical research issues such as trial ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
Breaking Biology News(10 mins):